France’s Sanofi (NASDAQ: SNY) has announced an extension of its 2019 collaboration with Nurix Therapeutics (NASDAQ: NRIX), a leader in targeted protein degradation, focusing on the drug target STAT6 for type 2 inflammation. The partners anticipate identifying a clinical candidate within the next year.
As part of the collaboration, Nurix has received $77 million to date for utilizing its drug discovery platform and stands to gain up to $2.5 billion in milestone payments, along with potential royalties from sales. Sanofi retains the option to license any resulting candidates.
Additionally, according to the public data, Nurix recently extended a similar agreement with U.S. counterpart Gilead (NASDAQ: GILD).- Flcube.com
